Hoth Therapeutics, Inc HOTH 深 滬
已收盤 05-08 16:00:00 美东时间
0.6701
-0.024
-3.44%
華盛通- 最 高0.6925
- 今 開0.69
- 成交量 25.04万股
- 最 低 0.6551
- 昨 收 0.694
- 總市值 1281.74万
- 52周最高 2.115
- 市盈率 靜 --
- 換手率 1.31%
- 52周最低 0.4894
- 委 比 6.38%
- 總股本 1912.76万
- 歷史最高 347.00
- 量 比 0.95
- 振 幅 5.39%
- 歷史最低 0.4894
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Hoth Therapeutics Launches Rocket One Space Subsidiary Initiative
The latest update is out from Hoth Therapeutics ( ($HOTH) ). On April 22, 2026,...
05-07 04:59
Hoth Therapeutics Secures Regulatory Authorization In Spain For Phase 2a CLEER Trial Of HT-001
Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment DisruptionsNEW YORK, May 5, 2026 /PRNewswire/ --
05-06 04:29
Hoth Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice
An update from Hoth Therapeutics ( ($HOTH) ) is now available. On April 30, 202...
05-05 07:15
Hoth Therapeutics Announces Data From Its HT-VA Study Demonstrating That Parenteral GDNF Directly Reprograms Liver Fat Metabolism At The Genetic Level In A Preclinical Model of Metabolically Associated Fatty Liver Disease
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement (CRADA) with the
04-14 05:27
Hoth Therapeutics Announces $2M Direct Offering At $0.70/Shr
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced that it has entered into a definitive agreement for
04-02 01:56
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering
NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs,...
04-02 01:52
Hoth Therapeutics Announces Over 65% Participants Demonstrate Meaningful Reductions In Pain, Itching In HT-001 Program; HT-001 Well Toleration, No Treatment Discontinuations Seen
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company, today announced positive clinical results from its ongoing HT-001 program, including achievement of the primary efficacy endpoint in
04-01 20:19
Hungary approves Hoth HT-001 Phase 2 trial expansion into Europe
Hungary approves Hoth HT-001 Phase 2 trial expansion into Europe Hungary granted regulatory clearance to expand Hoth Therapeutics’ Phase 2 HT-001 trial into Europe. Interim analysis showed HT-001 met primary endpoint, with patients reaching ARIGA rash severity score ≤1 by week six. Program update re
04-01 20:17
Hoth Therapeutics says HT-001 meets Phase 2 primary endpoint in interim analysis
Hoth Therapeutics says HT-001 meets Phase 2 primary endpoint in interim analysis Hoth Therapeutics reported interim Phase 2 results showing HT-001 met its primary efficacy goal by week six. Study update has already been presented via this interim analysis. Patients generally saw clear improvement in
04-01 20:14
BUZZ-U.S. STOCKS ON THE MOVE-DexCom, Ocugen, Estee Lauder
BUZZ-U.S. STOCKS ON THE MOVE-DexCom, Ocugen, Estee Lauder Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 24 (Reuters) - U.S. stock index futures pointed to a lower open on
03-24 21:10
